BIF acquires shares in Orbis Diagnostics Limited

Page 1 of 1


Booster Innovation Fund acquires share in Orbis Diagnostics Limited

20 May 2022
Booster Innovation Fund adds Orbis Diagnostics to its investment portfolio

Booster is pleased to announce the addition of Orbis Diagnostics to the Booster Innovation Fund (BIF)
portfolio, Orbis Diagnostics (formed in 2016) operates in the life sciences and medical technologies
sector. It specialises in the development of point of care diagnostics. It’s ‘lab in a box’ testing platform
uses its microfluidic disk to miniaturise and automate accurate lab testing for use at points of need. The
company is classified as early expansion stage.

BIF will make a cash investment of $250,000. Following this transaction (and issue of additional units to
fund the purchase), Orbis Diagnostics will represent 3% of BIF’s investment portfolio of 21 companies,
and with a net asset value of over $8.1m.

Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of
the process described in the fund’s Product Disclosure Statement (PDS) that is available at
www.booster.co.nz

For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-
innovation-fund.aspx




For more information, please contact:
Gary Scott
Company Secretary
Booster Investment Management Limited
04 8944300


About Booster
Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of
the Booster Group which has been helping New Zealanders save since 1998. The group currently
administers superannuation and investment funds of over $5 billion on behalf of more than 170,000 New
Zealanders.
BIF is a managed investment fund that invests in early-stage companies founded on intellectual property
originated or developed in New Zealand.
For more information, including a copy of the Product Disclosure Statement, please visit
www.booster.co.nz